Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Biotech Showcase 2016
27 slides from Prescient Therapeutics's conference presentation, Jan 11, 2016
Slide 1: ASX Release: PTX to present at Biotech Showcase 2016
ASX Release 11 January 2016 PTX to present at Biotech Showcase 2016 in San Francisco Melbourne, Australia 11 January 2016: Clinical stage oncology company, Prescient Therapeutics Ltd (PTX) advises that it will be presenting at the Annual Biotech Showcase in San Francisco, USA this week. Biotech Show
Slide 2: Blue chip US science yielding a deep clinical pipeline
Blue chip US science yielding a deep clinical pipeline » Phase Ib/II Breast cancer » Phase Ib Ovarian cancer » …and soon Phase Ib AML Biotech Showcase, San Francisco January 2016
Slide 3: Disclaimer and Safe Harbor
Disclaimer and Safe Harbor Certain statements made in this presentation are forward-looking statements within the meaning of the safe harbour provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are bas
Slide 4: Investment Highlights
Investment Highlights One of Deepest Clinical 3 clinical trials: 2 underway and 1 on track to initiate 1H 2016, all under Pipelines on ASX IND Two Clinical Stage 2 drug candidates targeting key cancer pathways Oncology Drugs » Akt (PTX-200) and Ras (PTX-100) Distinguished Scientific Compelling scien
Slide 5: Deep, Clinical Stage Product Pipeline
Deep, Clinical Stage Product Pipeline PTX has one of the deepest and most mature product pipelines on ASX Discovery Screening Preclinical Phase I Phase Ib Phase II Phase III PTX-200 Breast Cancer Finishing PTX-200 Ovarian Cancer Underway PTX-200 AML Early 2016 PTX-100 Breast Cancer PTX-100 Multiple
Slide 6: Corporate Snapshot
Corporate Snapshot Key Metrics Shareholder Base ASX Ticker PTX Total Issued Capital 93.7 M shares Board & 4.3 M Management: 14% Options (ex A$0.10; exp 12 Oct 2017) Share Price1 A$0.09 Market Capitalisation1 A$8.3 M Cash Position2 A$2.4 M Top 20 Own 33% 6 month turnover1 22.4 M shares Retail/HNW: 86
Slide 7: How Our Drugs Work: Molecular Switches
How Our Drugs Work: “Molecular Switches” Akt & Ras are growth factors PTX’s drugs block the Akt & found in cancer cells – Ras growth signals, when they are turned on, switching the growth signals they send a signal to the off and causing the cancer cancer cell to grow cell to die PTX-100 PTX-200 + c
Slide 8: PTX-200: Novel Akt inhibition
PTX-200: Novel Akt inhibition • Hyperactive Akt signaling: » Plays key role in many cancers including breast, ovarian, colorectal, PTX-200 (TCN-P) prostate, pancreatic and hematologic cancers » Confers resistance to chemotherapy » Strong pharma interest in Akt as a drug target PTX-200 • A small mole
Slide 9: PTX-200: Mechanism of Action – Normal Cell
PTX-200: Mechanism of Action – Normal Cell AKT is an ON/OFF switch that controls normal cell division Add Growth Factor Non-dividing Cell Dividing Cell AKT moves to cell membrane where it gets phosphorylated P Receptor Akt and activated to stimulate ON P cell division AKT is ON when phosphorylated a
Slide 10: PTX-200: Mechanism of Action – Cancer Cell
PTX-200: Mechanism of Action – Cancer Cell Some cancer cells contain Akt that is always phosphorylated* stimulating cells to divide forever Akt is stuck in the ON position Untreated Cancer Cell Akt ON P Synthesis Uncontrolled Growth TUMOR Cell Division 9 * (Switch in ON position)
Slide 11: PTX-200: Mechanism of Action – Treated Cancer Cell
PTX-200: Mechanism of Action – Treated Cancer Cell Prevents AKT from anchoring to membrane and causing cancer Treated Cancer Cells Treatment With PTX-200 Akt ON P Akt Prevents Akt from OFF moving to membrane keeping it in the OFF position Tumor Cells Stop Dividing 10
Slide 12: World Class Centers & Collaborations
World Class Centers & Collaborations New York Florida Previous clinical trials conducted at: 11
Slide 13: Drugs Don't Develop Themselves!
Drugs Don’t Develop Themselves! Said Sebti, PhD Terry Chew, M.D. Chief Scientific Officer Chief Medical Officer • Professor and Chair, Department of Drug Discovery - • Hematologist/oncologist with 20 years experience in biotech & Moffitt Cancer Center pharma • Co-Program Leader, Chemical Biology and
Slide 14: Clinical Advocates Driving Our Programs
Clinical Advocates Driving Our Programs Acute Myeloid Breast Cancer Ovarian Cancer Leukemia Joseph Sparano, M.D. Heather Han, M.D. Robert Wenham, M.D. Jeff Lancet, M.D. • Prof. of Medicine & • Assistant Prof. of • Section Head, • Prof. of Oncologic Obstetrics, Gynecology, Medicine at University Gyne
Slide 15: Board of Directors
Board of Directors • Experienced, complementary, and collaborative Steve Engle • Former Chairman and CEO of US-listed XOMA (NASDAQ:XOMA) and La Jolla Non-Executive Pharmaceuticals (NASDAQ: LJPC) Chairman • Currently CEO of Averigon Consulting, an advisory firm to life science industry • 25 years exp
Slide 16: World Class Scientific Advisory Board
World Class Scientific Advisory Board • Genuine international authorities, with particularly strong expertise in leukemia • Professor, Department of Leukemia, Division of Cancer Medicine, The University of Farhad Ravandi, Texas MD Anderson Cancer Center, Houston, Texas M.D. • Chief, Section of Devel
Slide 17: Breast Cancer Market Overview
Breast Cancer Market Overview • Breast cancer market currently US$10 B; due to double by 2023 • Most breast cancer drug sales are for HER2+ cancers, but this only represents ̴20% of all breast cancers • By contrast, PTX is targeting “HER2 negative” (HER2-) breast cancer • HER2- has “flown under the
Slide 18: Phase Ib Breast Cancer Trial Almost Completed
Phase Ib Breast Cancer Trial Almost Completed • PTX-200 plus Taxol in patients with metastatic and locally advanced breast cancer » Phase Ib trial currently underway » Recruiting at Albert Einstein College of Medicine Montefiore Medical Center Joseph Sparano, M.D. » Funded by National Cancer Institu
Slide 19: Phase II Breast Cancer Trial to Commence 1H 2016
Phase II Breast Cancer Trial to Commence 1H 2016 • Dr Heather Han at Moffitt to join Phase 2 recruitment • Phase II to commence 1H 2016 • Patients with metastatic and locally advanced breast cancer Joseph Sparano, M.D. • PTX-200 in combination with paclitaxel, followed by doxorubicin Principal Inves
Slide 20: Ovarian Cancer Market Overview
Ovarian Cancer Market Overview • One of the most common cancers in women -increasing with an ageing population • Due to reach US$1.7 B by 2019 » Market size currently constrained by old generic drugs that just aren’t good enough • Standard of care is “platinum based” drugs (often generic paclitaxel
Slide 21: Phase Ib Ovarian Cancer Trial Already Underway
Phase Ib Ovarian Cancer Trial Already Underway • PTX-200 plus Carboplatin in platinum resistant ovarian cancer • Significant need for new products to treat platinum-resistant ovarian cancer • Phase Ib already underway Robert Wenham, M.D. Principal Investigator • IND transferred to PTX (announced 29
Slide 22: Acute Myeloid Leukemia Market Overview
Acute Myeloid Leukemia Market Overview • AML is a type of cancer that affects the blood and bone marrow. » Patient cannot produce normal blood cells » Blood cells cannot function properly nor fight disease • Progresses very quickly & 5-year survival is a dismal 25% • More common in adults over 60 ye
Slide 23: PTX-200: Completed Phase I in AML
PTX-200: Completed Phase I in AML Patients 32 Trial Centers MD Anderson & Moffitt Patient Advanced hematologic malignancies (mainly AML) Inclusion Administration 1 hour IV infusion on days 1, 8, and 15. Methods Cycles repeated every 21 days. Study To establish dosing regime and biological dose Objec
Slide 24: Planned Phase Ib Trial: Acute Myeloid Leukemia
Planned Phase Ib Trial: Acute Myeloid Leukemia . • PTX-200 plus cytarabine in refractory or relapsed acute leukemia • Phase I results very encouraging • Phase Ib/II now planned • Protocol complete Jeffrey E Lancet, M.D. Principal Investigator • Moffitt Cancer Center ready to recruit • IND in final s
Slide 25: Catalysts To Watch Out For
Catalysts To Watch Out For 1H 2016 2H 2016 Phase Ib expansion Breast Complete Phase Ib cancer Initiate Phase II Initiate Phase Ib Ovarian Transfer Ovarian Cancer IND cancer Phase Ib dose escalation and interim analysis Complete Phase Ib IND allowed by US FDA Acute Myeloid Initiate Phase Ib Leukemia
Slide 26: Investment Summary
Investment Summary • Two clinical stage cancer drugs from top US institutions (Yale and Moffitt) • Two clinical trials currently underway: » Breast cancer » Ovarian cancer • 3rd trial starting early 2016 in Acute Myeloid Leukemia » A massive unmet market » Intense market interest • Gives Prescient o
Slide 27: Contact
Contact Steven Yatomi-Clarke Director Prescient Therapeutics Limited M: +61 417 601 440 E: [email protected] prescienttherapeutics.com